cyrilzakka/clinical-trials huggingface dataset:
Effects of Autogenic and Reciprocal Inhibition Techniques With Conventional Therapy in Mechanical Neck Pain

The objective of this randomized control trial is to determine the effectiveness of Autogenic and Reciprocal Inhibition techniques with conventional therapy in mechanical neck pain to improve Pain, Range of Motion, and Functional Disability in long term. This study is being conducted at the Physiotherapy department of Sindh Institute of Physical Medicine and Rehabilitation, Karachi (former institute of Dow University of Health Sciences) among 80 patients with mechanical neck pain on the basis of non-probability purposive sample technique with screening for study criteria through a consultant physician (blinded) . After taking informed consent all participants will be randomly allocated in two groups through second researcher who is not involved in screening, baseline assessment and providing intervention. Group 1 will receive Autogenic Inhibition muscle energy technique (MET) with conventional therapy and Group 2 will receive Reciprocal inhibition MET with conventional therapy. A total of 12 sessions will be provided. Outcomes will be assessed at baseline, after 1st session, and at last session.


Eligibility Criteria:
Inclusion Criteria:

* Moderate intensity (3.5-7.4cm) Pain on VAS
* Limited or Painful Cervical ROM
* Pain more than 4 weeks (sub-acute and chronic)
* 20-50 years Age

Exclusion Criteria:

* Any Symptom and sign of Radiculopathy and Myelopathy
* Any neurological disease like Multiple Sclerosis, Parkinson or Stroke
* Taking any Pain medication
* Trigger Point of Upper Trapezius
* Any fracture, surgical procedure, or trauma of the cervical spine
* Any red flag or signs of serious pathology like rheumatic or inflammatory diseases, malignancy, infection, or vascular disease such as Vertebro-Basilar Insufficiency.
Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia

The purpose of this study is to evaluate the efficacy and safety of combination therapy of omega-3-acids ethylesters 90/Atorvastatin calcium in type Ⅱb hyperlipidemia


Eligibility Criteria:
Inclusion Criteria:

* LDL≥160mg/dl, 200mg/dl≤TG\<500mg/dl
* In the case of smokers, he agrees should be smoke-free
* In the case of women of childbearing age, urine pregnancy test must be negative

Exclusion Criteria:

* Patients with acute artery disease within 3 months
* History of revascularization procedure or aneurism operation within 6months
* Patients with myopathy, rhabdomyolysis
* Patients with pancreatitis
* Patients with HIV positive
* History of malignant tumor within 2 years
* Patients must be treated with medications prohibited for concomitant use during study period
* Patients with uncontrolled hypertension(SBP\>180mmHg or DBP\>110mmHg)
* Serum Creatinine\>1.2mg/dl(female), \>1.4mg/dl(male)
* AST or ALT \> 2X ULN
* CPK \> 2X ULN
* Patients with galactose intolerance or Lapp lactase deficiency, glucose-galactose malabsorption
* Allergy or Hypersensitive to investigational drug
* History of drug or alcohol abuse within 2 years
* In the case of smokers, who do not intend to non smoking
* Women with pregnant, breast-feeding
* Patients treated with any investigational drugs within 1 month at the time consents are obtained
* Not eligible to participate for the study at the discretion of investigator
Peri-implant Soft Tissue and Bone Evaluation in Fully Computer Guided Immediate Implants

Prospective evaluation of perimplant soft tissue and bone response to one abutment one-time concept versus provisional abutment in fully guided single immediate implant placement.

Patient selection:

The study will be conducted on total of 16 patients recruited from the outpatient clinic of Oral Medicine, Periodontology, Oral Diagnosis and Radiology department, Faculty of Dentistry, Ain-Shams University. Sixteen consecutive healthy male/female patients with single non restorable remaining maxillary root from the right second premolar to the left second premolar will be added to the study.

Sample size analysis :

A sample size of 14 (7 in each group) will be sufficient to detect an effect size of approximately 1.75, with a power (1-β error) of 0.8 (80%) using a two-sided hypothesis test, with a significance level (α error) 0.05 for data. G power program version 3.1.9.2 was used for sample size calculation.This was increased to 8 patients in each group to make up for lost follow up cases The procedure will be explained to all patients and an informed consent will be signed before their inclusion in the study.

These patients will be divided randomly into 2 groups:

Group I: will include 8 patients who will undergo guided immediate implant placement and immediate provisionalization with preplanned PMMA provisional restoration on Ti-Base Group II: will include 8 patients who will undergo guided immediate implant placement and immediate loading by using a final CAD/CAM customized abutment and a cemented CAD/CAM fabricated PMMA provisional restoration.

Eligibility Criteria:
Inclusion Criteria:

* Males and females aged at least 18 years.
* Patients free from any systemic disease as evidenced by health questionnaire - - Single tooth failure of a maxillary anterior region (incisors, canines, and premolars) with neighbouring teeth present and healthy periodontal conditions.
* Intact socket walls evident on cone beam computed tomography and confirmed on the day of extraction.
* Natural teeth present adjacent to the tooth being replaced in addition to a natural counterpart tooth present for esthetics criteria evaluation.
* Adequate bone apical to the tooth to be replaced with a minimum primary stability of 30 Ncm.
* Thick gingival biotype.

Exclusion Criteria:

* Presence of active infection around the failing tooth or adjacent teeth.
* Presence of active periodontal disease and gingival recession in the esthetic area.
* Systemic diseases , pregnancy and smoking.
* Recent orthodontic treatment.
* Bruxism and parafunctional habits .
* Labial plate dehiscence, fenestration, or loss after tooth extraction
* Inability to achieve primary stability after implant placement
* Vulnerable groups: prisoners, mentally retarded, etc
Childhood Autism Risks From Genetics and the Environment (The CHARGE Study)

The purpose of this study is to understand how genes, environment, and the interplay between the two, influences the development of autism and other neurodevelopmental disorders.

The causes and contributing factors for autism are poorly understood. Evidence suggests that incidence is increasing, but diagnostic changes and improvements may be playing a role. Both genetic and environmental factors appear to play a role. Autopsy studies demonstrate structural changes in the brain and clinical investigations reveal neurophysiologic differences in information processing in autistic versus normal children. Members of our team recently demonstrated altered levels of certain neuropeptides at birth in children who later developed autism.

This case-control study is the first large-scale epidemiologic investigation of underlying causes for autism and triggers of regression. This study capitalizes on the strengths of the case-control design, which is well suited to examine a broad array of factors for rare conditions that are thought to be multifactorial. Comparisons will be made with both general population controls and mentally retarded children.

The aims are to assess the influence of exogenous exposures, the role of susceptibility factors, and the interplay between these two in the etiology of autism and its phenotypic variation. Chemicals with known or suspected neurodevelopmental toxicity, such as PCB's, certain pesticides, and metals, are being investigated. This study pursues several hypotheses that have recently gained attention, including the combined measles, mumps, rubella vaccine and mercury present in vaccines given during infancy and early childhood. Additionally, biochemical susceptibility is examined through characterization of metabolic, immunologic, and neuronal gene expression profiles and genetic polymorphisms.

Eligibility Criteria:
Inclusion Criteria:

* Children between 2 and 5 years old
* Born in California
* Parents must speak either English or Spanish
* Children must be living with at least one biologic parent

Exclusion Criteria:

* Children not meeting eligibility criteria listed above
* Children not residing in selected geographical areas (please contact for more information about specific study locations)
Rosacea Treatment Using Non-thermal (cold) Atmospheric Plasma Device

10-13 patients will be enrolled to receive split face treatment: the control side will be treated with metronidazole cream, the intervention side will be treated with a cold atmospheric plasma device


Eligibility Criteria:
Inclusion Criteria:

* Papulopustular rosacea of the cheeks
* Ability to complete six weeks of twice-weekly treatments

Exclusion Criteria:

* substantial asymmetry of disease distribution
* previous failure of topical ivermectin treatment
* presence of any other facial dermatoses
* presence of any photosensitizing disorders
* systemic tetracycline, systemic or topical ivermectin treatment within 6 weeks of start date
* current or within prior 3 months treatment with systemic immune-suppressive medication
A Prospective Trial of an Endoscopic Quality Improvement Project

Randomized prospective multi-site validation study.

GI practice sites that have recently agreed to participate in the GIQuIC program will be randomized on a site-basis, to the EQUIP intervention or control.

Baseline ADR and polyp/surveillance predication accuracy will be collected for approximately 3 months.

Sites randomized to the EQUIP intervention will undergo face-to-face training by a study investigator, followed by active monitoring and feedback.

Control sites will not receive supplemental training and will be monitored by with no feedback. After completion of the study all sites will be offered the intervention (as is standard feedback in GIQuIC ).

Eligibility Criteria:
Inclusion Criteria:

* Endoscopy centers that are new to GIQuIC and have not yet received training
* All endoscopists performing screening and surveillance colonoscopy at the participating center will be invited to participate

Exclusion Criteria:

* Cases that involve acute indications such as bleeding and active colitis will not be included in data pool
* Patients with a family or personal history of a polyposis syndrome or with a personal history of inflammatory bowel disease will also be excluded
* Procedures that are deemed incomplete will be excluded
* Patients with surgically altered anatomy (i.e. prior colectomy) and with poor bowel preparation (Boston bowel preparation score \<5, or inadequate to exclude polyps \>5mm) will be excluded
Assisted Hatching Versus Endometrial Scratch in Recurrent Implantation Failure

300 recurrent implantation failure patients will be alternatively assigned to assisted hatching , endometrial scratch , and no treatment ,100 patients in each group

Group 1 consists of 100 patients will undergo endometrial scratch followed by controlled ovarian hyperstimulation Group 2 consists of 100 patients will undergo controlled ovarian hyperstimulation\& assisted hatching Group 3 consists of 100 patients will undergo controlled ovarian hyperstimulation

Eligibility Criteria:
Inclusion Criteria:

* recurrent implantation failure
* normal uterine cavity by transvaginal ultrasound

Exclusion Criteria:

* endometrial polyp or fibroid distorting the endometrium
* hydrosalpinx
* preimplantation genetic diagnosis
* severe male factor
Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects

This study is conducted in Asia. The aim of this observational study is to investigate the percentage of patients reaching the treatment target on blood glucose control after treatment with either human insulin or insulin analogues in type 2 diabetes subjects inadequately controlled with two or more oral antidiabetic drugs in China. Further the safety profiles will be evaluated.


Eligibility Criteria:
Inclusion Criteria:

* After the investigator has taken the decision to use human insulin or insulin analogues to treat the subject, any type 2 diabetic previously inadequately controlled with two or more OADs is eligible for the study
* The selection of the subjects will be at the discretion of the individual investigator

Exclusion Criteria:

* Known or suspected allergy to trial product(s) or related products
* Subjects who are unlikely to comply with protocol requirements, e.g. uncooperative attitude, inability to return for the final visit
* Subjects who previously enrolled in this study
* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods
* The receipt of any investigational product within 3 months prior to this trial
Relative Hand Grip Strength and Functional Fitness in Diabetic Patient in Egypt

To show if there is significant relationship between hand grip strength and physical fitness in diabetic type II patients over 60 years old.

To show if there is significant relationship between hand grip strength and physical fitness in diabetic type II patients over 60 years old.

Eligibility Criteria:
Inclusion Criteria:

* Diabetes type II
* Ability to walk independently
* The cognitive and mental capacity to understand and perform tests

Exclusion Criteria:

* Musculoskeletal, neurological, rheumatological problems, or hand deformities that could hinder grasping
A Study Pilot About the Contribution of Pleuropulmonary Echography Iin Acute Bronchiolitis Among Infants

Pleuropulmonary echography remains an almost non-existent tool in routine pediatric practice.

Our study is part of a desire to develop its use in pediatrics, in particular for the diagnosis of acute bacterial pneumonitis associated with acute bronchiolitis among infants.


Eligibility Criteria:
Inclusion Criteria:

* Infants aged \<= 2 years old
* Medical diagnosis of acute bronchiolitis requiring hospitalization in the pediatric departments of the Besançon University Hospital
* No opposition from the parents for performing the pleuropulmonary echography.

Exclusion Criteria:

* Children aged \> 2 years old
* Infants aged \< 2 years old consultant in pediatric emergencies for acute bronchiolitis without subsequent hospitalization.
* Previous chronic lung disease (including pulmonary bronchodysplasia), unoperated congenital heart disease or neuromuscular disease.
The Utility of Cap Colonoscopy in Increasing Adenoma Detection Rate

This is a research study about the usefulness of transparent cap during screening colonoscopy. The purpose of the research is to test the usefulness of adding small cap to the tip of the colonoscope. the investigators hypothesis is that Cap assisted colonoscopy will improve the detection of adenomatous polyps (polyps which can become colon cancer later on) in comparison to the standard colonoscopy.

This is a prospective, randomized trial comparing the adenoma detection rate between Hispanic patients undergoing a screening colonoscopy with a conventional colonoscope or with a cap-assisted colonoscopy. The aims of the study are:

1. Compare ADR between Hispanic patients undergoing a screening colonoscopy with and without cap.
2. Compare the overall polyp detection rate between Hispanic patients undergoing a screening colonoscopy with and without cap.
3. Compare the cecal intubation rate and cecal intubation time between standard colonoscopy and cap assisted colonoscopy.
4. Compare the complication rate between standard colonoscopy and cap assisted colonoscopy.

Eligibility Criteria:
Inclusion Criteria:

* Adult Hispanic patients (18-80) who are undergoing colonoscopy for screening or surveillance purposes.

Exclusion Criteria:

1. Patients younger than 18 yrs old or older than 80 yrs.
2. Patients with a prior history of colonic surgeries
3. Patient with Crohns colitis or ulcerative colitis.
4. Patient with prior history of colon cancer
5. Patient with poor bowel preparation
Role of Acetylcysteine in Creatinine Clearance

The purpose of this study is to investigate the exact role of Acetylcysteine (Mucomyst) in altering creatinine clearance. Prior studies have shown the protective effects of Acetylcysteine on contrast-induced renal dysfunction. In these studies, Acetylcysteine lowered the incidence of serum creatinine elevation after administration of radiographic contrast agents. Not only was the increase in serum creatinine prevented, the studies also demonstrated a significant increase in creatinine clearance after administration of the agent. These prior studies did not evaluate if the increase in creatinine clearance was indeed from a protective benefit of Acetylcysteine in preserving the GFR versus simply increasing the proximal tubular creatinine secretion without actually affecting the GFR. We propose an experiment to help support our hypothesis that Acetylcysteine increases creatinine clearance via an increase in proximal tubular secretion of creatinine.


Eligibility Criteria:
Inclusion Criteria:

1. Between the ages of 18 and 79 years
2. In good general health
3. Able to provide informed consent

Exclusion Criteria:

1. Allergy to acetylcysteine or cimetidine,
2. Age less than 18 years or greater than 79 years of age,
3. Women of childbearing age and not able to use adequate contraception, or 4. Anyone currently on any medication that interferes with tubular secretion of creatinine such as trimethoprim-sulfamethoxazole (Bactrim).
Beta-alanine Supplementation and High-intensity Interval Training

The present study will seek to quantify whether a period of HIIT alongside β-alanine supplementation will improve the adaptation to training, and therefore performance, more than a period of HIIT alone.

Whilst high-intensity interval training (HIIT) is a powerful stimulus to increase endurance exercise performance, there are potential nutritional interventions that can be put in place to further increase performance gains.

Energy for the contraction of muscles is created in the mitochondria. HIIT can improve the function of mitochondria, therefore improving performance.

Β-alanine is a commonly used supplement that can improve exercise performance by increasing the amount of carnosine in muscle. Carnosine has many functions that may help improve exercise capacity.

The present study will seek to quantify whether a period of HIIT alongside β-alanine supplementation will improve the adaptation to training, and therefore performance, more than a period of HIIT alone.

Eligibility Criteria:
Inclusion Criteria:

* Moderately trained (vo2max: 50 - 60 ml/kg/min).
* Females must be taking an oral contraceptive, or using a contraceptive implant.

Exclusion Criteria:

* A recent history of musculoskeletal injury
* Diagnosed cardiovascular or metabolic disease
* Regular use of beta-alanine supplements
The Effect of Inhibitory Kinesio Taping Application on Spasticity, Stretch Reflex and Motor Neuron Activity

The first aim of this study is whether the inhibitory kinesio taping application can reduce spasticity. The second aim of this study is to investigate whether the kinesio taping application have neuromodulatory activity on motor neuron and stretch reflex.

Hypotheses of this study: unlike healthy cases, in patients with spastic hemiplegia

1. Inhibitory kinesio taping application can reduced spasticity
2. Inhibitory kinesio taping application can reduced motor neuron activity and stretch reflex

This study will include 78 spastic hemiplegic patient ( 39 controlled, 39 intervention group) Spasticity , Soleus Hmax/Mmax, Soleus T reflex, Soleus H reflex will be evaluated in this study.

Inhibitory kinesio taping method will be used in intervention group for 64-66 hours. Y shaped kinesio tape will be applied on spastic gastrocsoleus muscle. Sham kinesio taping method will be used in controlled group for 64-66 hours. 2 pieces kinesio tape 2,5 cm width, 5 cm length will be applied on gastrocnemius medial and lateral head, 1 piece kinesio tape 5 cm width, 5 cm length will be applied on achilles tendon.

Spasticity, Soleus Hmax/Mmax, Soleus T reflex and H reflex will be measured pre-application (T0), after-application ( in a few minutes) (T1), after 64-66 hours ( with band applied) (T2) and after band removed (T3). Spasticity in both groups will be evaluated with modified ashworth scale.

Eligibility Criteria:
Inclusion Criteria:

* Unilateral ischemic/hemorrhagic stroke
* First stroke attack
* Gastrocsoleus muscle spasticity ( Modified Ashworth Scale 1-3)

Exclusion Criteria:

* Perform surgery from the related limb
* Skin problems, wounds and infections
* Allergy to the kinesio tape material
* Antispastic drug use
* Contracture in gastrocsoleus muscle or antagonists
* Peripheral nerve lesion in the lower extremity
* II.Motor neuron diseases
Intracoronary Stem Cells in Large Myocardial Infarction

Despite the widespread use of effective reperfusion therapies, the patients presenting late with large myocardial infarction have poor outcomes. The aim of the study was to investigate the safety and efficacy of intracoronary injection of autologous bone marrow-derived mononuclear cells (BMNCs) in patients with large myocardial infarction

In the current era, up to 30% of patients with ST-segment elevation myocardial infarction, usually those presenting late, show ongoing left ventricular (LV) remodeling and poor clinical outcome despite primary percutaneous coronary intervention (PCI). Cardiac transfer of bone marrow-derived stem and progenitor cells has been investigated as an adjunctive therapy to promote regeneration of infarcted myocardium. Therefore, we designed a multicenter, randomized study to test the safety and efficacy of intracoronary injection of autologous BMNCs in patients with large acute anterior myocardial infarction and late presentation, who were treated with successful primary PCI.

Eligibility Criteria:
Inclusion Criteria:

* Patients with the first ST-segment elevation acute anterior myocardial infarction due to occlusion of the proximal left anterior ascending coronary artery (LAD), who will underwent successful primary stented PCI. Patients are eligible if they have primary PCI from 4 to 12 hours after symptoms onset and show reduced LV ejection fraction ≤ 45% with at least 3 akinetic segments in the LAD perfusion territory at echocardiogram performed 24 hours after PCI.

Exclusion Criteria:

* Exclusion criteria are age ≥ 80 years, cardiogenic shock (Killip IV), multivessel coronary artery disease, serious renal or hepatic disease, blood cells disorders, documented cancer or terminal illness.